Evidence map›Paper›PMID 39385301›Full record

ArticleCell & bioscience2024

CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma.

Suet Kee Loo, Gabriel Sica, Xian Wang, Tingting Li, Luping Chen, Autumn Gaither-Davis, Yufei Huang, Timothy F Burns, Laura P Stabile, Shou-Jiang Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell & bioscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Suet Kee LooCancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Gabriel SicaDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Xian WangCancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Tingting LiCancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Luping ChenCancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Autumn Gaither-DavisDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Yufei HuangCancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Timothy F BurnsDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Laura P StabileCancer Biology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Shou-Jiang GaoCancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. gaos8@upmc.edu.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
Cell Model for KSHV Infection and Genetic ManipulationR01CA096512 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Shou-Jiang Gao · 2003 to 2026
$7.4M
Regulation of KSHV replication by N6-methyladenosine (m6A) - Diversity SupplementR01CA124332 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GAO, SHOU-JIANG · 2007 to 2025
$5.0M
Impact of microbiota on AIDS-Kaposi’s sarcoma development and therapyR01CA284554 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shou-Jiang Gao · 2023 to 2026
$3.1M
Citrulline-urea cycle in KSHV cellular transformationR01CA278812 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shou-Jiang Gao · 2023 to 2026
$2.1M
National Institute of Health CA096512National Institute of Health CA124332National Institute of Health CA278812National Institute of Health CA284554NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA096512NCI NIH HHS R01 CA124332NCI NIH HHS R01 CA278812NCI NIH HHS R01 CA284554
6 · The paper itself

Abstract

backgroundLung cancer, a leading global cause of cancer-related mortality, necessitates enhanced prognostic markers for improved treatment outcomes. We have previously shown a tumor suppressive role of cytosolic arginine sensor for mTORC1 subunit 1 (CASTOR1), which is targeted for degradation upon phosphorylation at S14 (pCASTOR1) in multiple types of cancer. This study focuses on the predictive value of pCASTOR1 in lung adenocarcinoma (LUAD) patients with KRAS mutations.

resultsEmploying a newly developed pCASTOR1 specific antibody, we found that tumor cells exhibited significantly elevated pCASTOR1 scores compared to non-tumor cells (P < 0.05). Higher pCASTOR1 scores predicted poorer overall survival (OS) (HR = 3.3, P = 0.0008) and relapse-free survival (RFS) (HR = 3.0, P = 0.0035) in male patients with KRAS mutations. pCASTOR1 remained an independent predictor for OS (HR = 4.1, P = 0.0047) and RFS (HR = 3.5, P = 0.0342) after controlling for other factors. Notably, in early-stage LUAD, elevated pCASTOR1 scores were associated with significantly worse OS (HR = 3.3, P = 0.0176) and RFS (HR = 3.1, P = 0.0277) in male patients with KRAS mutations, akin to late-stage patients.

conclusionElevated pCASTOR1 scores serve as biomarkers predicting poorer OS and RFS in male LUAD patients with KRAS mutations, offering potential clinical utility in optimizing treatment strategies for this subgroup.

Indexed as

BiomarkerCytosolic arginine sensor for mTORC1 subunit 1, CASTOR1KRASLung adenocarcinoma, LUADMammalian target of rapamycin complex 1, mTORC1

Identifiers

PMID39385301
PMCPMC11465729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.